Dante Labs presents the progress of its drug discovery development program, demonstrating the value of genomic data for drug discovery

New York, May 31, 2022 (Globe Newswire) – Dante’s genomicsA global leader in genomics and precision medicine, the company is currently in the pipeline with six drug candidates making significant progress in its drug discovery development program, applying in-house siRNA and mRNA technology for rare and frequent diseases from Dante.

Since the company’s inception, Dante has invested in a powerful R&D program aimed at creating end-to-end solutions from diagnosis to treatment. The dental program began with a focus on rare diseases, in response to a diagnosis of a rare disease that had no cure. Dante’s portfolio has evolved across multiple therapeutic fields, four drug programs towards full internal development and two towards co-development and validation and external partnerships for clinical trials and commercialization.

“Personalized drugs require personalized data, and only in the last 18 months has our progress demonstrated the value of genomic data for research and drug discovery,” said Andrea Riposati, CEO of Dante Genomics. “When we established Dante’s Genomics, we realized that we had a responsibility to provide personal care outside of diagnosis so that no patient would be diagnosed without effective treatment. It is this holistic approach that challenges us and inspires us to accelerate science to save more lives as a company. A

Dante has advanced his internal medicine programs in rare muscle diseases, rare neurological diseases and immunology to the pre-clinical stage. The latest addition to Dante’s portfolio of discovery programs is a molecular discovery-level mRNA oncology treatment aimed at increasing immunity against certain types of cancer. The U.S. biotech company, in co-development with Protelica, provides therapies for dental respiratory disease and ovarian cancer, both at the non-regulatory preclinical stage.

Development of Dante’s covid mRNA vaccine program began in early 2021 and recently the regulatory pre-clinical phase was completed and it was ready for the first human inoculation.

“My academic experience has taught me the value of RNA therapy, and Dante’s use of mRNA and siRNA technologies to accelerate in-house R&D patient concepts into clinical practice,” said Matia Capuli, Scientific Director at Dante Genomics. “Data from our MRNA vaccine program and rapid advances demonstrate the high quality of Dante’s RNA platform and the fertility of this model applied to other clinical therapies.

To better reflect its global efforts in genomic information and personalized medicine, the company has announced that it has changed its name to Dante Genomic. The company name, Dante comes from the connection between genomics, humanity and science. “Dante” refers to the Italian humanist poet and “genomics” refers to the powerful science that takes place in a genomics lab. Since its inception, Dante Genomics has provided thousands of people with affordable, quality genomics solutions to support their health decisions. The company’s overall approach to drugs extends from sequencing and variant interpretation to drug discovery.

About Dante’s genomics

Dante Genomics is a global genomics information company that is creating and commercializing a new class of transformative health and longevity applications based on genome sequencing and artificial intelligence. The company uses its platform to improve patient outcomes from diagnosis to therapy, including one of the largest private genome databases with research consent, a proprietary software platform designed to publish power scale genomic data and patent processes for genomics. Enables the industrial approach. Sequencing

Contact:

Laura D’Angelo
Vice President of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantegenomics.com

A picture is available with this press release https://www.globenewswire.com/NewsRoom/AttachmentNg/5e163117-b6e3-40cc-8ecc-48cd9d72e8ce


Print friendly, PDF and email

Leave a Comment